NYSE$AMWL

American Well Corp · Q3 2021 earnings

Q3 2021 earnings · · Investor relations

Briefing

Announced results for the third quarter of 2021.

Amwell's total revenue was $62.2 million, with a gross margin of 43.5%. The company had a net loss of $50.9 million and an adjusted EBITDA of ($31.5) million. Total active providers were approximately 80,000 and total visits were approximately 1.4 million.

  • Revenue of $62.2 million in the third quarter
  • Gross margins of 43% of revenue compared to 33% last year
  • Total visits of 1.4 million
  • Total active providers of approximately 80,000 at the end of the third quarter versus 71,000 last quarter and 62,000 last year

Headline financials

Total Revenue

$62.2M

Previous: $62.6M-0.5%
EPS (adj)

-$4.00

Previous: -$18.40+78.3%
Total Visits

1.4M

Previous: 1.4M-1.0%
Gross Margin

43.5%

Previous: 32.7%+33.0%
Capital Expenditures

-$221K

Previous: -$3.26M+93.2%
Free Cash Flow

-$51.7M

Previous: -$66.3M+22.0%
Net Income

-$51.5M

Previous: -$63.1M+18.4%
Operating Income

-$55.5M

Previous: -$64.3M+13.7%
Gross Profit

-$55.5M

Previous: -$64.3M+13.7%
Cash & Equivalents

$790M

Previous: $956M-17.4%
Total Assets

$1.48B

No prior period
Stock-Based Comp

$12.4M

No prior period

Revenue & EPS history

American Well · Revenue · Quarterly

$62.2M

Q3 2021-0.5%vs Q3 2020
Beat estimate in 5 of 9 quarters(56%)
ActualEstimate

Revenue by segment

American Well · $56.7M total across 2 segments · Q3 2021

  • AMG Visit Revenue
    $30M+5.3%
  • Subscription Revenue
    $26.7M+3.5%

Forward guidance

For 2021, the Company is narrowing and adjusting their previous visits outlook as a direct result of the impact of the COVID-Delta variant and now expects: Revenue between $246 and $253 million and Adjusted EBITDA between ($143) and ($136) million.

Tailwinds

  • Acknowledges gross margin expansion due to visit mix shift more toward high margin urgent care
  • Overall operational efficiencies

Headwinds

  • Revenue between $246 and $253 million from the previous range of $252 to $262 million
  • Mainly to account for decreases in visit volume
  • Shifts in visit-type mix toward urgent care versus specialty due to the COVID-Delta variant
  • AMG visit volume to end the year at the lower quartile of the range of 1.4 and 1.5 million
  • Adjusted EBITDA between ($143) and ($136) million from the previous range of ($154) and ($146) million

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q3 2021

Historical avgQ3 2021

+1.4%

Avg return

Earnings day

+2.1%

Avg return

5 days after

-2.2%

Avg return

30 days after

41%

9 / 22 earnings

Positive

+33.8%

Q2 2024

Best reaction

-20.9%

Q1 2021

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-2.0%+27.2%+34.0%
Q4 2025+24.7%+34.9%+29.8%
Q3 2025-9.5%-20.0%-20.6%
Q1 2025+19.7%+9.5%+8.9%
Q4 2024-5.0%-3.6%-35.5%
Q3 2024-5.0%-5.4%-0.7%
Q2 2024+33.8%+13.9%-1.1%
Q1 2024+2.0%+11.4%-16.3%
Q4 2023+23.6%+20.8%-16.0%
Q3 2023+14.5%+4.3%+11.1%
Q2 2023-8.3%-13.9%-35.2%
Q1 2023-3.9%-2.9%+17.9%
Q4 2022-13.1%-19.2%-37.3%
Q3 2022-2.2%+14.9%-8.3%
Q2 2022+9.2%+6.8%-4.8%
Q1 2022-10.8%+8.8%+37.6%
Q4 2021+7.2%+1.0%-8.0%
Q3 2021-7.4%-3.7%-29.7%
Q2 2021+0.7%-1.7%+0.8%
Q1 2021-20.9%-5.7%+9.5%
Q4 2020-4.1%-10.8%-1.5%
Q3 2020-11.9%-19.8%+17.1%
Q2 2020
Q1 2020
Q4 2019
Q3 2019
Q2 2019
Q1 2019

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro